The Efficacy of Preoperative Administration of a Single Dose of Recombinant Human Erythropoietin in Pediatric Cardiac Surgery
DOI:
https://doi.org/10.1532/HSF98.20061183Abstract
Background. Preoperative autologous blood donation with recombinant human erythropoietin (rHuEPO) is effective in adults. However, there are problems concerning the blood access, cost, and blood storage in children. The purpose of this study was to evaluate the efficacy of administering a single dose of rHuEPO without blood donation in children undergoing pediatric cardiac surgery.
Methods. Eighty-two children (72 with noncyanotic heart disease, and 10 with cyanotic heart disease) whose hematocrit values were less than 45% were included in this prospective, nonrandomized study. The children were divided into 3 groups: group E0 (n = 20) was not treated with rHuEPO and iron sulfate; group E2 (n = 27) was treated with 200 IU/kg of rHuEPO and 2 mg/kg of iron sulfate; and group E4 (n = 35) was treated with 400 IU/kg of rHuEPO and 4 mg/kg of iron sulfate. Administration of rHuEPO was performed subcutaneously 7 days before the operation. The hematological and iron parameters were measured perioperatively.
Results. A lower proportion of children treated with rHuEPO (group E2, 14.8%; group E4, 22.9%) than children without rHuEPO (group E0, 40.0%) were exposed to RBC transfusions; however, there was no significance. The elevations of the hematocrit levels were 0.7% in group E0, 1.3% in group E2, and 1.9% in group E4. The elevation of the hematocrit was greater in patients with anemia (hematocrit ?37%).
Conclusions. Although the effectiveness for avoiding transfusion was not clear, the administration of a single dose of rHuEPO without autologous blood donations had an effect by increasing hematocrit levels.
References
Bennett CL, Luminari S, Nissenson AR, et al. 2004. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403-8.nBidstrup BP, Royston D, Sapsford RN, et al. 1989. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97:364-72.nCook DJ, Orszulak TA, Daly RC, et al. 1997. Minimum hematocrit for normothermic cardiopulmonary bypass in dogs. Circulation 96:II200-4.nCoyle D, Lee KM, Fergusson DA, et al. 2000. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 18:161-71.nD'Ambra MN, Gray RJ, Hillman R, et al. 1997. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 64:1686-93.nDe Andrade JR, Jove M, Landon G, et al. 1996. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25:533-42.nEngoren MC, Habib RH, Zacharias A, et al. 2002. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74:1180-6.nFukahara K, Murakami A, Ueda T, et al. 1997. Scheduled autologous blood donation at the time of cardiac catheterization in infants and children. J Thorac Cardiovasc Surg 114:504-5.nHaga P, Cotes PM, Till JA, et al. 1987. Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease. Blood 70:822-6.nHardy JF, Belisle S, Janvier G, et al. 1996. Reduction in requirements for allogeneic blood products: nonpharmacologic methods. Ann Thorac Surg 62:1935-43.nJacobs K, Shoemaker C, Rudersdorf R, et al. 1985. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806-10.nKiyama H, Ohshima N, Imazeki T, et al. 1999. Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg 68:1652-6.nKuehnert MJ, Roth VR, Haley NR, et al. 2001. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41:1493-9.nKurth CD, Steven JM, Nicolson SC, et al. 1997. Cerebral oxygenation during cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 113:71-9.nMasuda M, Kawachi Y, Inaba S, et al. 1995. Preoperative autologous blood donations in pediatric cardiac surgery. Ann Thorac Surg 60:1694-7.nMichalopoulos A, Tzelepis G, Dafni U, et al. 1999. Determinants of hospital mortality after coronary artery bypass grafting. Chest 115:1598-603.nMiyake T, Kung CK, Goldwasser E. 1977. Purification of human erythropoietin. J Biol Chem 252:5558-64.nOotaki Y, Yamaguchi M, Oshima Y, et al. 2002. Effects of modified ultrafiltration on coagulation factors in pediatric cardiac surgery. Surg Today 32:203-6.nOotaki Y, Yamaguchi M, Yoshimura N, et al. 2004. Efficacy of a criterion driven transfusion protocol in pediatric cardiac surgery patients. J Thorac Cardiovasc Surg 127:953-8.nShimpo H, Mizumoto T, Onoda K, et al. 1997. Erythropoietin in pediatric cardiac surgery: clinical efficacy and effective dose. Chest 111:1565-70.nSowade O, Warnke H, Scigalla P, et al. 1997. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 89:411-8.nStrauss RG. 1994. Can the cost of erythropoietin for cardiac surgery patients be justified? Transfusion 34:835.nTyndall MR, Teitel DF, Lutin WA, et al. 1987. Serum erythropoietin levels in patients with congenital heart disease. J Pediatr 110:538-44.nWatanabe Y, Fuse K, Konishi T, et al. 1991. Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg 51:767-72.nYazicioglu L, Eryilmaz S, Sirlak M, et al. 2001. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg 122:741-5.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
